Skip to Content

Nydrazid (isoniazid) Disease Interactions

There are 5 disease interactions with Nydrazid (isoniazid):


Inh (Includes Nydrazid) ↔ Hepatotoxicity

Severe Potential Hazard, High plausibility

Applies to: Liver Disease, Alcoholism

The use of isoniazid is contraindicated in patients with acute liver disease or a history of hepatic injury due to isoniazid. Caution is advised when using the drug in patients with chronic liver disease or a history of alcoholism. Isoniazid has been associated with severe and sometimes fatal hepatitis, which may occur even after many months of therapy. In a US Public Health Service Surveillance Study of nearly 14,000 isoniazid patients, the incidence of hepatitis was 1.25%, of which 4.6% was fatal. However, more recent studies have reported considerably lower rates when CDC guidelines for selection and monitoring of patients were followed. Epidemiologic studies indicate an increased incidence with increasing age, alcohol use, and female gender. As a precautionary measure, routine monitoring of serum transaminases (SGOT, SGPT) and bilirubin may be considered, although a transient and harmless increase in serum transaminase reportedly occurs in 10% to 20% of patients, usually in the first 3 months of therapy. Patients should be advised to promptly discontinue isoniazid therapy and seek medical attention if they experience signs or symptoms suggestive of liver damage such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Reinstitution of the drug should occur only after symptoms and laboratory abnormalities resolve, with low and gradually increasing dosages.


  1. Maddrey WC "Drug-related acute and chronic hepatitis." Clin Gastroenterol 9 (1980): 213-24
  2. U.S. Departmnet of Health and Human Services / Public Health Service "Severe isoniazid-associated hepatitis--New York, 1991-1993." MMWR Morb Mortal Wkly Rep 42 (1993): 545-7
  3. Moulding TS, Redeker AG, Kanel GC "Twenty isoniazid-associated deaths in one state." Am Rev Respir Dis 140 (1989): 700-5
  4. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.
  5. Yamamoto T, Suou T, Hirayama C "Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype." Hepatology 6 (1986): 295-8
  6. Mitchell JR, Zimmerman HJ, Ishak KG, et al "Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis." Ann Intern Med 84 (1976): 181-92
  7. Maddrey WC, Boitnott JK "Isoniazid hepatitis." Ann Intern Med 79 (1973): 1-12
  8. Bartelink AK, Lenders JW, van Herwaarden CL, et al "Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy." Tubercle 64 (1983): 125-8
  9. Dutt AK, Moers D, Stead WW "Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis." Am Rev Respir Dis 128 (1983): 419-24
  10. Israel HL, Gottlieb JE, Maddrey WC "Perspective: preventive isoniazid therapy and the liver." Chest 101 (1992): 1298-301
  11. Maddrey WC "Isoniazid-induced liver disease." Semin Liver Dis 1 (1981): 129-33
  12. Snider DE, Caras GJ "Isoniazid-associated hepatitis deaths: a review of available information." Am Rev Respir Dis 145 (1992): 494-7
  13. Yoshikawa TT, Nagami PH "Adverse drug reactions in TB therapy: risks and recommendations." Geriatrics 37 (1982): 61-8
  14. Franks AL, Binkin NJ, Snider DE, et al "Isoniazid hepatitis among pregnant and postpartum Hispanic patients." Public Health Rep 104 (1989): 151-5
  15. "Product Information. Nydrazid (isoniazid)" Apothecon Inc, Princeton, NJ.
View all 15 references

Inh (Includes Nydrazid) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Isoniazid is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from isoniazid due to decreased drug clearance. Dosage reductions are recommended in these patients.


  1. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.
  2. Reed MD, Blumer JL "Clinical pharmacology of antitubercular drugs." Pediatr Clin North Am 30 (1983): 177-93
  3. Acocella G, Bonollo L, Garimoldi M, et al "Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease." Gut 13 (1972): 47-53
  4. "Product Information. Nydrazid (isoniazid)" Apothecon Inc, Princeton, NJ.
  5. Weber WW, Hein DW "Clinical pharmacokinetics of isoniazid." Clin Pharmacokinet 4 (1979): 401-22
  6. Ellard GA, Gammon PT "Pharmacokinetics of isoniazid metabolism in man." J Pharmacokinet Biopharm 4 (1976): 83-113
View all 6 references

Inh (Includes Nydrazid) ↔ Peripheral Neuropathy

Severe Potential Hazard, High plausibility

Applies to: Malnourished, Diabetes Mellitus, Alcoholism, Peripheral Neuropathy

Isoniazid commonly causes dose-related peripheral neuropathy, which results from the depletion of pyridoxine in the presence of the drug. The neuropathy is usually preceded by paresthesias of the feet and hands. Therapy with isoniazid should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes and alcoholism. Pyridoxine (vitamin B6) at a dosage of 10 to 50 mg/day may prevent or attenuate isoniazid-related peripheral neuropathy and is recommended for these patients.


  1. Dippenaar J, Jameson C, Dowse R "Side-effects of isoniazid." S Afr Med J 72 (1987): 89
  2. Siskind MS, Thienemann D, Kirlin L "Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature." Nephron 64 (1993): 303-6
  3. "Product Information. Nydrazid (isoniazid)" Apothecon Inc, Princeton, NJ.
  4. Mandell GL, Bennett JE, Dolin R, eds.. "Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed." New York, NY: Churchill Livingston 1 (1995):
  5. Gonzalez-Gay MA, Sanchez-Andrade A, Aguero JJ, Alonso MD, Rodriguez E, Criado JR "Optic neuritis following treatment with isoniazid in a hemodialyzed patient." Nephron 63 (1993): 360
  6. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.
  7. Jimenez-Lucho VE, del Busto R, Odel J "Isoniazid and ethambutol as a cause of optic neuropathy." Eur J Respir Dis 71 (1987): 42-5
View all 7 references

Inh (Includes Nydrazid) ↔ Hemodialysis

Moderate Potential Hazard, High plausibility

Applies to: hemodialysis

Isoniazid is substantially removed by hemodialysis and should be administered after dialysis.


  1. "Product Information. Nydrazid (isoniazid)" Apothecon Inc, Princeton, NJ.
  2. Gold CH, Buchanan N, Tringham V, et al "Isoniazid pharmacokinetics in patients with chronic renal failure." Clin Nephrol 6 (1976): 365-9
  3. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.

Inh (Includes Nydrazid) ↔ Renal Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Isoniazid is metabolized primarily by acetylation and dehydrazination in the liver. It is not significantly excreted by the kidney. Dosage adjustments in renal impairment are generally not necessary except in slow acetylators with a creatinine clearance below 10 mL/min. The rate of acetylation is genetically determined. Approximately 50% of blacks and caucasians are slow acetylators, and the majority of Eskimos and Asians are rapid acetylators.


  1. "Product Information. Nydrazid (isoniazid)" Apothecon Inc, Princeton, NJ.
  2. Gold CH, Buchanan N, Tringham V, et al "Isoniazid pharmacokinetics in patients with chronic renal failure." Clin Nephrol 6 (1976): 365-9
  3. "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.
  4. Boxenbaum HG, Bekersky I, Mattaliano V, Kaplan SA "Plasma and salivary concentrations of isoniazid in man: preliminary findings in two slow acetylator subjects." J Pharmacokinet Biopharm 3 (1975): 443-56
  5. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH "Tuberculosis in patients with end-stage renal disease." Am J Med 68 (1980): 59-65
  6. Mitchison DA, Ellard GA "Tuberculosis in patients having dialysis." Br Med J 280 (1980): 1533
  7. Kim YG, Shin JG, Shin SG, Jang IJ, Kim SG, Lee JS, Han JS, Cha YN "Decreased acetylation of isoniazid in chronic renal failure." Clin Pharmacol Ther 54 (1993): 612-20
  8. Bowerson DW, Winterbauer RH, Stewart GL, et al "Isoniazid dosage in patients with renal failure." N Engl J Med 289 (1973): 84-7
  9. Reidenberg MM, Shear L, Cohen RV "Elimination of isoniazid in patients with impaired renal function." Am Rev Respir Dis 108 (1973): 1426-8
View all 9 references

Nydrazid (isoniazid) drug Interactions

There are 510 drug interactions with Nydrazid (isoniazid)

Nydrazid (isoniazid) alcohol/food Interactions

There are 2 alcohol/food interactions with Nydrazid (isoniazid)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.